Can occult metastases be treated by radioimmunotherapy?

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2656-2659

  Dunn, Robert M ^a   Juweid, Malik ^a   Sharkey, Robert M ^a   Behr, Thomas M ^b   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Dosimetry; Minimal residual disease; Monoclonal antibodies; Occult metastases; Radioimmunotherapy

Indexed keywords

IMMUNOGLOBULIN G; IODINE 131; MONOCLONAL ANTIBODY I 131;

ALPHA RADIATION; CONFERENCE PAPER; CONTROLLED STUDY; ELECTRON; LIVER; METASTASIS; NONHUMAN; OCCULT CANCER; PHANTOM; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SIMULATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME;

EID: 0031472246     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2656::aid-cncr42>3.0.co;2-8     Document Type: Conference Paper

References (13)

1. 2. J Nucl Med 1994;37:1504-10.
2. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine, 1988.
3. Bardiès M, Chatal JF. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. Phys Med Biol 1994;39:961-81.
4. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. MIRD Pamphlet No 7. J Nucl Med 1971;12 (Suppl 5):5-23.
5. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993;94:297-312.
6. Larson SM, Leibel SA, Cheung NKV. Radiosiotope conjugates. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. Philadelphia: J.B. Lippincott, 1991:496-511.
7. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990;50:1039s-1042s.
8. Blumenthal RD, Sharkey RM, Kashi R, Natale AM, Goldenberg DM. Influence on animal host and tumor implantation site on radioantibody uptake in the GW-39 human co-Ionic xenograft. Int J Cancer 1989;44:1041-7.
9. Hagan PI, Halpern SE, Dillman RO, et al. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986;27:422-7.
10. Moshakis V, Mcilhinney RAJ, Raghavan D, Neville AM. Localization of human tumor xenografts after intravenous administration of radiolabeled monoclonal antibodies. Br J Cancer 1981;44:91-9.
11. O'Donoghue JA, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1994;36:1902-9.
12. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, Van Osdol W, et al. The micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-53.
13. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med 1990;31:75-83.